Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
about
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyAdvances in immunotherapy for melanomaMechanism-Based Strategies for the Management of Autoimmunity and Immune Dysregulation in Primary ImmunodeficienciesAdverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case ReportsPhase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignanciesAntibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Combination immunotherapy: a road map.Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy studyA phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Tremelimumab-Induced Graves Hyperthyroidism.Cancer Immunotherapy: Whence and Whither.How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD.Immunotherapy: a new treatment paradigm in bladder cancer.Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review.Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature.Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.The current status of checkpoint inhibitors in metastatic bladder cancer.Regulatory T Cells: Central Concepts from Ontogeny to Therapy.Cancer immunotherapy in patients with preexisting autoimmune disorders.Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Immunotherapy of colorectal cancer: new perspectives after a long path.Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature.Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Meta-analysis of the risk of immune-related adverse events with anti-cytotoxic T-lymphocyte-associated antigen 4 and anti-programmed death 1 therapies.Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.Targeting Immunotherapy to the Tumor Microenvironment.Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.Immunotherapy of cancers comes of age.The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination TherapyCheckpoint inhibitors for malignant melanoma: a systematic review and meta-analysisPD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomyImmune-related adverse events during anticancer immunotherapy: Pathogenesis and management."Neurological complications of new chemotherapy agents".
P2860
Q26745516-DD635271-1453-4F40-B610-6F75BBB36679Q26768558-1D82A486-0610-428C-8A73-60F3ACD80455Q28066193-C76CA99B-0D4F-43EE-BE20-FC6BB7CABBBCQ28553328-5B08322A-79FD-40C3-9288-21AFBD10DA3BQ33572971-602690B7-1154-4EF5-8873-89308F45923FQ33699687-1F9F110F-FDDD-4639-A491-5EBFDB903234Q34552128-89BEA16F-0E28-4DCF-86AA-B7A380D59E1EQ36170378-01684600-C0D3-4CC1-91FF-D72CABEA1423Q36687229-2B80147F-0DB2-4783-BA2F-27D986B404ADQ37518314-3B2207C3-744C-4C2C-A230-10AD0D4B1361Q37702430-FEF9BC61-D86F-4B23-9E59-5F8C1CB658BCQ38635780-E7F73F0A-E3F4-4B7D-9764-94008AAFD66BQ38737924-05E2E5F3-236B-4478-94C6-911E3AFBEC75Q38739354-AD56A164-750E-45A4-895C-AA0CF31DD828Q38743589-F481A26E-9619-4154-9362-5D1A8386496AQ38783026-F6DCD330-E3D5-4A0A-84C6-ADB1D730720EQ38824550-F5841941-A560-4666-B226-349ACCCC08FDQ38833996-9B713B7A-5214-4987-A33B-DB1EC3F1586EQ38884560-0FCF6AB3-5B16-4D6E-8B85-9A19FC21710AQ38886982-3BB97349-F19F-45FD-8735-DD719D78D0CEQ38927531-D7139EBA-A263-4F8B-8117-65750CA9F681Q38978399-0133628D-D761-4E3D-9FE5-450EF094183CQ39004668-F5215E2F-CC46-47F4-B45D-ACA59254D795Q39009781-9E046860-1849-439E-9612-35A7A20295B2Q39043413-AE8F9B36-A676-4316-BC39-500F26A409E4Q39044741-D7109CB3-A014-4675-AF1B-8423AD619661Q39045600-2EB95C0D-3CD2-41B7-8796-9DDD6EB40909Q39085984-6E86533F-00F4-4CC3-8474-5475CD70BF4EQ39101223-A38F2865-799A-4360-B1CD-FA573ED5BB7CQ39159356-1068E9A9-8F6B-4923-8497-CD795C3182AEQ39195213-7B86E6AA-F18D-4F85-A86A-4AAFBCCD2A13Q39308337-2DEA5068-7F8C-4AC0-A7F2-E433A333DAF2Q39413457-A4B41112-091B-4319-A51B-541D30D6401FQ40099075-8E8660EF-BDC3-4C9F-B724-767B1479E2A0Q40387345-4F2DC001-2F41-4350-A661-4AD3A60A5458Q41485890-606AFD47-C44D-4ED7-9306-0AC9A7BC3CA3Q41590737-8B332A3B-EF05-405F-A9C6-A394094AB1ACQ42366515-8806D834-96C8-4AA9-9F60-79C1738ED5C6Q45026631-10836EA2-3906-4B6C-B73F-B1D128E6BD85Q45069581-603B1816-1A8E-4138-848D-25B8C032A908
P2860
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
description
2015 nî lūn-bûn
@nan
2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Immune related adverse events ...... matic review and meta-analysis
@ast
Immune related adverse events ...... matic review and meta-analysis
@en
Immune related adverse events ...... matic review and meta-analysis
@nl
type
label
Immune related adverse events ...... matic review and meta-analysis
@ast
Immune related adverse events ...... matic review and meta-analysis
@en
Immune related adverse events ...... matic review and meta-analysis
@nl
prefLabel
Immune related adverse events ...... matic review and meta-analysis
@ast
Immune related adverse events ...... matic review and meta-analysis
@en
Immune related adverse events ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P921
P3181
P1433
P1476
Immune related adverse events ...... matic review and meta-analysis
@en
P2093
Anne Bertrand
Marie Kostine
Marie-Elise Truchetet
Thomas Barnetche
P2860
P2888
P3181
P356
10.1186/S12916-015-0455-8
P407
P5008
P577
2015-09-04T00:00:00Z
P5875
P6179
1007367199